Sugi Predict

Sugi Predict / Compounds / SCHEMBL4376141

SCHEMBL4376141

SCHEMBL4376141

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)sc3C(=O)O)cc2)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 10/20 0.61
▸ EPHX2 P34913 4/20 0.61
▸ KDR P35968 5/20 0.61
▸ MAPK14 Q16539 10/20 0.57
▸ ABL1 P00519 4/20 0.57
▸ RET P07949 3/20 0.57
▸ EPHA2 P29317 3/20 0.57
▸ MAP3K20 Q9NYL2 3/20 0.57
▸ MAPK13 O15264 3/20 0.57
▸ PLK4 O00444 2/20 0.57
▸ AURKA O14965 2/20 0.57
▸ MAP4K4 O95819 2/20 0.57
▸ LCK P06239 2/20 0.57
▸ FYN P06241 2/20 0.57
▸ LYN P07948 2/20 0.57
▸ SRC P12931 2/20 0.57
▸ RPS6KB1 P23443 2/20 0.57
▸ AXL P30530 2/20 0.57
▸ FRK P42685 2/20 0.57
▸ MAPK9 P45984 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13625511 0.85 RAF1 (0.61) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL4367329 0.85 MAPK14 (0.63) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL4376263 0.83 MAPK14 (0.50) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL4370809 0.82 MAPK14 (0.51) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL257980 0.82 RAF1 (0.82) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL4371790 0.81 MAPK14 (0.53) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL171336 0.80 DDR2 (0.52) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL12391532 0.80 RAF1 (0.76) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL1532339 0.79 RAF1 (0.77) RAF1EPHX2KDRMAPK14ABL1
SCHEMBL10163311 0.78 RAF1 (0.76) RAF1EPHX2KDRMAPK14ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612200-B2 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2009-11-03 — — US disclosed
US-7612200-B2 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2009-11-03 — — US disclosed
US-7612200-B2 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2009-11-03 — — US disclosed
US-20090192307-A1 INHIBITORS OF PROTEIN KINASES LOCUS PHARMACEUTICALS, INC. 2009-07-30 — — US disclosed
US-20090192307-A1 INHIBITORS OF PROTEIN KINASES LOCUS PHARMACEUTICALS, INC. 2009-07-30 — — US disclosed
US-20090192307-A1 INHIBITORS OF PROTEIN KINASES LOCUS PHARMACEUTICALS, INC. 2009-07-30 — — US disclosed
EP-1824843-A2 INHIBITORS OF PROTEIN KINASES Locus Pharmaceuticals, Inc. (US) 2007-08-29 — — EP disclosed
WO-2006062984-A2 INHIBITORS OF PROTEIN KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192307-A1 INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K19 RAF1 37/4885EPHX2 3099/4885KDR 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.